NVO241122P102000
- 0.03
- -0.60-95.24%
Novo-Nordisk A/S Newsroom
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $156
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Cantor Fitzgerald Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Erste Group Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $156
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $155